Cardiovascular Diabetology

OCTOBER 18, 2024

Type 2 diabetes mellitus (T2DM) is a major risk factor for heart failure with preserved ejection fraction and cardiac arrhythmias. Precursors of these complications, such as diabetic cardiomyopathy, remain inc.

Preserved Ejection Fraction 52

Preserved Ejection Fraction Diabetes Risk Factors Heart Failure 52

American College of Cardiology

NOVEMBER 18, 2024

What is the incremental benefit in patients with heart failure and preserved ejection fraction (HFpEF) of glucagon-like peptide-1 receptor agonists (GLP-1 RA) combined with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) and body mass index (BMI) ≥27?

Preserved Ejection Fraction 69

Preserved Ejection Fraction BMI Heart Failure Diabetes 69

American College of Cardiology

JANUARY 15, 2025

Alison Bailey and Milton Packer examine the power of tirzepatide expanding beyond weight loss and treating diabetes in addition to reducing heart failure events in patients with obesity-related HFpEF. In this interview, Drs.

Preserved Ejection Fraction 45

Preserved Ejection Fraction Heart Failure Obesity Diabetes 45

European Journal of Heart Failure

DECEMBER 7, 2023

Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Obesity Heart Failure BMI 40

DAIC

JUNE 21, 2024

announced that the peer-reviewed Journal of the American College of Cardiology: Heart Failure has published a research paper concluding that INPEFA (sotagliflozin) is cost-effective for people with diabetes and recent worsening heart failure using commonly accepted willingness-to-pay thresholds. “Our healthcare system. “Our

Heart Failure 105

Heart Failure Preserved Ejection Fraction Diabetes Research 105

American College of Cardiology

APRIL 10, 2024

What are the effects of semaglutide across a broad range of outcomes in people with obesity-related heart failure with preserved ejection fraction (HFpEF) with and without diabetes, and consistency across key patient subgroups?

Preserved Ejection Fraction 56

Preserved Ejection Fraction Obesity Heart Failure Diabetes 56

Circulation

OCTOBER 13, 2023

BACKGROUND:Apparent treatment-resistant hypertension (aTRH) is prevalent and associated with adverse outcomes in heart failure with mildly reduced or preserved ejection fraction. Less is known about the potential role of sodium-glucose co-transporter 2 inhibition in this high-risk population.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Hypertension Myocardial Infarction 40

European Journal of Heart Failure

MARCH 4, 2024

Patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) have a high risk of developing LRTI. Prior studies were able to show that sodium–glucose cotransporter 2 inhibitors may reduce the incidence of LRTI in patients with type 2 diabetes. Patients who developed LRTI had a 2.7-fold

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure COVID-19 Kidney Disease 40

American College of Cardiology

JUNE 24, 2024

Semaglutide reduces body weight to a greater extent in women with obesity-related heart failure with preserved ejection fraction (HFpEF) than in men, and improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) to the same extent in both women and men, according to results from a prespecified secondary analysis of pooled (..)

Preserved Ejection Fraction 62

Preserved Ejection Fraction Obesity Heart Failure Cardiomyopathy 62

European Journal of Heart Failure

OCTOBER 9, 2023

Impact of COVID-19 in patients with HF and mildly reduced and preserved ejection fraction. Methods and results Participants with chronic heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) were randomized to dapagliflozin or placebo across 350 sites in 20 countries.

Preserved Ejection Fraction 40

Preserved Ejection Fraction COVID-19 Heart Failure Hospital 40

Cardiovascular Diabetology

AUGUST 15, 2024

Patients with diabetes have an increased risk of developing heart failure with preserved ejection fraction (HFpEF). This study aimed to compare indices of myocardial deformation and perfusion between patients.

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Diabetes Research 52

Circulation

NOVEMBER 11, 2024

The eventful subjects had a higher prevalence of diabetes, higher estimated pulmonary pressure, lower hemoglobin levels and was less on treatment with renin-angiotensin system inhibitors.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Diabetes Hospital 40

Circulation: Heart Failure

NOVEMBER 25, 2024

Spironolactone reduced HF events in some patients with HF with preserved ejection fraction, but the results were not generalizable to all patients with HF with preserved ejection fraction.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Myocardial Infarction Kidney Disease 40

Open Heart

NOVEMBER 27, 2023

LD use was highest among HF with reduced EF (HFrEF) patients (81.1%) followed by HF with mild-reduced EF (76.1%) and HF with preserved ejection fraction EF (73.8%, p<0.001). Among all LDs users, the median FDE was 40 mg (IQR: 40–80). Renal impairment was associated with a higher FDE across the entire EF spectrum.

Heart Failure 52

Heart Failure Preserved Ejection Fraction Outpatient Diabetes 52

Cardiometabolic Health Congress

NOVEMBER 14, 2024

42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. Additionally, 10% of the global population suffers from chronic kidney disease , with diabetes and hypertension as significant risk factors. In the U.S., SELECT Trial Results : Semaglutide 2.4

CME 103

CME Obesity Heart Failure Biomarkers 103

Cardiometabolic Health Congress

NOVEMBER 22, 2024

Heart Failure Management : The FINEARTS-HF trial focused on the efficacy of finerenone, an aldosterone antagonist, in reducing heart failure hospitalizations and cardiovascular mortality among patients with preserved ejection fraction (HFpEF). New developments in continuous glucose monitors (CGMs) have also been transformative.

Blood Pressure 59

Blood Pressure Obesity Coronary Artery Disease Preserved Ejection Fraction 59

CardiacWire

AUGUST 2, 2024

Lilly’s blockbuster GLP-1 tirzepatide appears poised to become the next major HFpEF drug, after topline results from the SUMMIT trial showed that it significantly improved both outcomes and symptoms among patients with heart failure with preserved ejection fraction and obesity.

Outcomes 59

Outcomes Preserved Ejection Fraction Heart Failure Obesity 59

DAIC

FEBRUARY 29, 2024

12:15 p.m.

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

Circulation: Cardiovascular Imaging

JANUARY 13, 2025

BACKGROUND:In patients with heart failure with preserved ejection fraction (HFpEF), the impact of type 2 diabetes (T2D) on left ventricular global longitudinal strain (LV GLS) and its prognostic implications remains unclear. Circulation: Cardiovascular Imaging, Ahead of Print.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Cardiovascular Imaging Heart Failure Outcomes 40

European Journal of Heart Failure

NOVEMBER 19, 2024

Shortly after delivery, women who experienced HDP express increased risk of classic CV risk factors such as hypertension, renal disease, abnormal lipid profile, and diabetes. Women with HDP demonstrated impaired myocardial function, biventricular chamber dysfunction and adverse biventricular remodelling.

Risk Factors 40

Risk Factors Heart Failure Hypertension Preserved Ejection Fraction 40

Cardiometabolic Health Congress

JULY 25, 2023

There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] I think we live in a very exciting time right now for those who work in diabetes and cardiovascular disease.

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

Cardiology Update

APRIL 9, 2024

STEP-HFpEF DM 5 ( NCT04916470 ) explored the effects of semaglutide in obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes. TACT-2 8 ( NCT02733185 ) assessed if chelation therapy could reduce recurrence of cardiac events in diabetic patients with prior MI. Presented at: ACC 2024.

Myocardial Infarction 52

Myocardial Infarction Angina Aortic valve Coronary Artery Disease 52

European Journal of Heart Failure

FEBRUARY 4, 2024

Phenomics analyses identified unique druggable inflammatory markers in HFpEF from the tumour necrosis factor receptor superfamily (TNFRSF), which were positively associated with hypertension, diabetes, and increased posterior and relative wall thickness.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Biomarkers Hypertension 40

DAIC

JUNE 26, 2024

Getty Images milla1cf Wed, 06/26/2024 - 18:59 June 26, 2024 — Semaglutide , a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options.

Preserved Ejection Fraction 105

Preserved Ejection Fraction Obesity BMI Heart Failure 105

Journal of the American Heart Association

JANUARY 23, 2025

BackgroundCardiometabolic comorbidities such as obesity, diabetes, and hypertension are highly prevalent in heart failure (HF). Journal of the American Heart Association, Ahead of Print. Severely uncontrolled comorbidities were defined as systolic blood pressure 160 mm Hg, hemoglobin A1c 8%, and body mass index 35 kg/m2.

Heart Failure 40

Heart Failure Preserved Ejection Fraction Obesity Outcomes 40

The British Journal of Cardiology

JANUARY 14, 2025

We report from the 19 th Annual Scientific Meeting of the Cardiorenal Forum held in London on 4 th October 2024, which served as a dynamic platform for experts in cardiology, diabetes, and renal medicine to converge and exchange the latest insights on managing heart and kidney failure.

Innovation 40

Innovation Diabetes Preserved Ejection Fraction Outcomes 40